Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of farletuzumab ecteribulin (MORAb-202) vs investigator’s choice chemotherapy in platinum-resistant high-grade serous ovarian, primary peritoneal, or fallopian tube cancer
2023-504111-33-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of farletuzumab ecteribulin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Objective response rate (ORR) and Treatment-related adverse events leading to discontinuation. Started Feb 2023; status: completed.
02
Drugs
farletuzumab ecteribulin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2023-504111-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504111-33-00.